Kyntra Bio reports Q1 2026 net loss of $15.1M ($3.74/share) and cash runway into 2028

KYNTRA BIO, INC.

2026-Q1 EPS reported -$3.76 vs consensus -$3.42 ▼ miss (-9.9%)

Phase 2 trial of FG-3246 in mCRPC enrolling; interim analysis expected in 4Q 2026.
Positive combo data with enzalutamide: median rPFS 7.0 mo overall, 10.1 mo in 1 prior ARPI.
Pivotal Phase 3 protocol for roxadustat in LR-MDS being finalized after FDA feedback; trial start H2 2026.
Revenue $3.7M (up from $2.7M); net loss $15.1M vs $16.8M YoY.
Cash and equivalents $100.3M; sufficient to fund operations into 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

KYNTRA BIO, INC. reported first quarter 2026 results: revenue $3.7 million, net income $15.1 million, or $3.74 net loss per basic and diluted share, EPS $3.74 net loss per basic and diluted share.

Period: first quarter 2026
Revenue: $3.7 million
Net income: $15.1 million, or $3.74 net loss per basic and diluted share
EPS: $3.74 net loss per basic and diluted share
Result: reported results

Exact text from the filing

Total revenue from continuing operations for the first quarter of 2026 was $3.7 million, as compared to $2.7 million for the first quarter of 2025. • Net loss from continuing operations for the first quarter of 2026 was $15.1 million, or $3.74 net loss per basic and diluted share, compared to a net loss of $16.8 million, or $4.15 net loss per basic and diluted share, one year ago.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-216731

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.